{"nctId":"NCT01008995","briefTitle":"A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis","startDateStruct":{"date":"2009-10"},"conditions":["Psoriasis"],"count":322,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: placebo","Drug: ustekinumab"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: placebo","Drug: ustekinumab"]}],"interventions":[{"name":"placebo","otherNames":[]},{"name":"ustekinumab","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"ustekinumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must be of Chinese ancestry\n* Have had a diagnosis of plaque-type psoriasis at least 6 months prior to study start\n* Have plaque-type psoriasis covering at least 10% of total BSA at screening and at the time of study start\n* Have a Psoriasis Area and Severity Index (PASI) score of 12 or greater at study start\n* Must be candidates for phototherapy or systemic treatment of psoriasis (either naive or history of previous treatment)\n\nExclusion Criteria:\n\n* Currently have nonplaque forms of psoriasis\n* Have current drug-induced psoriasis\n* Have used any investigational drug within the previous 4 weeks\n* Have used any biologic within the previous 3 months\n* Be known to be infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Patients Who Achieved at Least a 75% Improvement in PASI (Psoriasis Area and Severity Index) From Baseline at Week 12.","description":"Scores could range from 0 (mild) to 72 (severe).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"132","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Patients With a Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"126","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change in Dermatology Life Quality Index (DLQI) From Baseline at Week 12.","description":"Scores could range from 0 to 30. A lower DLQI score represents better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"6.63"},{"groupId":"OG001","value":"-9.3","spread":"7.18"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":161},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}}